NO20040097L - Kombinasjoner for behandling av inflammatoriske forstyrrelser - Google Patents

Kombinasjoner for behandling av inflammatoriske forstyrrelser

Info

Publication number
NO20040097L
NO20040097L NO20040097A NO20040097A NO20040097L NO 20040097 L NO20040097 L NO 20040097L NO 20040097 A NO20040097 A NO 20040097A NO 20040097 A NO20040097 A NO 20040097A NO 20040097 L NO20040097 L NO 20040097L
Authority
NO
Norway
Prior art keywords
combinations
treatment
inflammatory disorders
disorders
inflammatory
Prior art date
Application number
NO20040097A
Other languages
English (en)
Norwegian (no)
Inventor
Curtis Keith
Robyn Sackeyfio
Jason Fong
Nicole Hurst
Palaniyandi Manivasakam
Edward Roydon Jost-Price
Grant Zimmerman
Alexis Borisy
Original Assignee
Combinatorx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23174998&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20040097(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Combinatorx Inc filed Critical Combinatorx Inc
Publication of NO20040097L publication Critical patent/NO20040097L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Physics & Mathematics (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Analytical Chemistry (AREA)
  • Rheumatology (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
NO20040097A 2001-07-09 2004-01-09 Kombinasjoner for behandling av inflammatoriske forstyrrelser NO20040097L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US30408901P 2001-07-09 2001-07-09
PCT/US2002/020142 WO2003006026A1 (en) 2001-07-09 2002-06-26 Combinations for the treatment of inflammatory disorders

Publications (1)

Publication Number Publication Date
NO20040097L true NO20040097L (no) 2004-03-01

Family

ID=23174998

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20040097A NO20040097L (no) 2001-07-09 2004-01-09 Kombinasjoner for behandling av inflammatoriske forstyrrelser

Country Status (23)

Country Link
US (5) US6897206B2 (is)
EP (1) EP1414466B1 (is)
JP (1) JP2004534841A (is)
KR (1) KR20040026680A (is)
CN (1) CN1553804A (is)
AR (1) AR034746A1 (is)
AT (1) ATE439844T1 (is)
AU (1) AU2002310511B2 (is)
BR (1) BR0211062A (is)
CA (1) CA2453399A1 (is)
DE (1) DE60233414D1 (is)
ES (1) ES2330837T3 (is)
HR (1) HRP20040102A2 (is)
IL (1) IL159771A0 (is)
IS (1) IS7099A (is)
MX (1) MXPA04000222A (is)
NO (1) NO20040097L (is)
NZ (1) NZ530764A (is)
PL (1) PL368045A1 (is)
RU (1) RU2300379C2 (is)
SG (1) SG152907A1 (is)
WO (1) WO2003006026A1 (is)
ZA (1) ZA200401004B (is)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60233414D1 (de) * 2001-07-09 2009-10-01 Combinatorx Inc Kombinationen für die behandlung entzündlicher erkrankungen
US20040220153A1 (en) * 2002-09-24 2004-11-04 Jost-Price Edward Roydon Methods and reagents for the treatment of diseases and disorders associated with increased levels of proinflammatory cytokines
ES2343411T3 (es) 2003-03-26 2010-07-30 Synergy Biosystems Ltd. Procedimientos para identificar agentes biologicamente activos y combinaciones sinergicas.
KR20060076319A (ko) * 2003-09-24 2006-07-04 콤비네이토릭스, 인코포레이티드 약물 조합들을 투여하는 치료 요법
US20060287246A1 (en) * 2003-09-24 2006-12-21 Shinji Yoneda Remedy for eye diseases accompanied by optic nerve injuries
TW200517114A (en) * 2003-10-15 2005-06-01 Combinatorx Inc Methods and reagents for the treatment of immunoinflammatory disorders
CN1901863A (zh) * 2003-11-13 2007-01-24 康宾纳特克斯公司 治疗炎性疾病的方法和药物
US8119154B2 (en) 2004-04-30 2012-02-21 Allergan, Inc. Sustained release intraocular implants and related methods
KR101314461B1 (ko) 2004-05-12 2013-10-07 더 브리검 앤드 우먼즈 하스피털, 인크. 감염 치료를 위한 겔솔린의 용도
WO2005115455A2 (en) * 2004-05-17 2005-12-08 Combinatorx, Incorporated Methods and reagents for the treatment of immunoinflammatory disorders
WO2006006152A2 (en) * 2004-07-08 2006-01-19 Ramot At Tel-Aviv University Ltd Treatment of disorders and diseases of the colon
US7553496B2 (en) * 2004-12-21 2009-06-30 University Of Kentucky Research Foundation VEGF-A as an inhibitor of angiogenesis and methods of using same
TW200711649A (en) * 2005-06-17 2007-04-01 Combinatorx Inc Combination therapy for the treatment of immunoinflammatory disorders
US20070299043A1 (en) * 2005-10-03 2007-12-27 Hunter William L Anti-scarring drug combinations and use thereof
WO2007041677A2 (en) * 2005-10-03 2007-04-12 Combinatorx, Incorporated Soft tissue implants and drug combination compositions, and use thereof
JP2009523029A (ja) 2006-01-10 2009-06-18 コルゲート・パーモリブ・カンパニー 炎症の予防または軽減のために、細胞表面受容体を調節する方法
US20090054763A1 (en) * 2006-01-19 2009-02-26 The Regents Of The University Of Michigan System and method for spectroscopic photoacoustic tomography
EP3279663B1 (en) * 2006-03-15 2021-07-28 The Brigham and Women's Hospital, Inc. Use of gelsolin to diagnose and treat inflammatory diseases
MX2008014828A (es) * 2006-05-22 2009-02-06 Combinatorx Inc Metodos y composiciones para el tratamiento de enfermedades o condiciones asociadas con niveles incrementados de proteina c-reactiva, interleucina-6 o interferon-gamma.
DK2124857T3 (en) * 2007-01-09 2017-07-03 Fovea Pharmaceuticals DEVICE FOR INTRAOCULAR INJECTION
GB0701170D0 (en) * 2007-01-22 2007-02-28 Imp Innovations Ltd Compositions and uses thereof
WO2008118426A1 (en) * 2007-03-26 2008-10-02 Combinatorx, Incorporated Split dose corticosteroid therapy
RU2469715C2 (ru) * 2007-04-30 2012-12-20 Адолор Корпорейшн Композиции (-)-e-10-oh-nt и способы их синтеза и применения
US20110009351A1 (en) * 2007-05-09 2011-01-13 Traffick Therepeutics Inc. Screening assay to identify correctors of protein trafficking defects
US9701747B2 (en) 2007-05-21 2017-07-11 Alderbio Holdings Llc Method of improving patient survivability and quality of life by anti-IL-6 antibody administration
CN101754772B (zh) 2007-05-21 2015-08-19 奥尔德生物控股有限责任公司 针对il-6的抗体及其用途
US7906117B2 (en) 2007-05-21 2011-03-15 Alderbio Holdings Llc Antagonists of IL-6 to prevent or treat cachexia, weakness, fatigue, and/or fever
US8252286B2 (en) 2007-05-21 2012-08-28 Alderbio Holdings Llc Antagonists of IL-6 to prevent or treat thrombosis
US8062864B2 (en) 2007-05-21 2011-11-22 Alderbio Holdings Llc Nucleic acids encoding antibodies to IL-6, and recombinant production of anti-IL-6 antibodies
US8178101B2 (en) 2007-05-21 2012-05-15 Alderbio Holdings Inc. Use of anti-IL-6 antibodies having specific binding properties to treat cachexia
US8404235B2 (en) 2007-05-21 2013-03-26 Alderbio Holdings Llc Antagonists of IL-6 to raise albumin and/or lower CRP
US9511076B2 (en) * 2008-05-30 2016-12-06 Clarion Research Group Formulations and methods for recovery from dental surgery
GB0715428D0 (en) * 2007-08-08 2007-09-19 Imp Innovations Ltd Compositions and uses thereof
CA2737131A1 (en) * 2007-09-19 2009-03-26 Zalicus Inc. Therapeutic regimens for the treatment of immunoinflammatory disorders
JP2011506607A (ja) * 2007-12-17 2011-03-03 ザリカス インコーポレイティッド 免疫炎症性障害の処置のための治療法
DK2250280T3 (en) 2008-01-25 2015-03-09 Gen Hospital Corp THERAPEUTIC USES OF gelsolin in renal failure
PT2262506E (pt) * 2008-03-11 2014-06-24 Alcon Res Ltd Suspensões de acetonido de triamcinolona de baixa viscosidade altamente floculadas para injeção intravítrea
US8883768B2 (en) * 2008-04-18 2014-11-11 Warsaw Orthopedic, Inc. Fluocinolone implants to protect against undesirable bone and cartilage destruction
ME01516B (me) 2008-06-20 2014-04-20 Astrazeneca Ab DERIVAT DIBENZOTIAZEPINA l NJEGOVA UPOTREBA
WO2010013240A1 (en) * 2008-07-31 2010-02-04 Dekel Pharmaceuticals Ltd. Compositions and methods for treating inflammatory disorders
WO2010021681A2 (en) * 2008-08-18 2010-02-25 Combinatorx (Singapore) Pte. Ltd. Compositions and methods for treatment of viral diseases
GB2463883A (en) * 2008-09-25 2010-03-31 Pharma Patents Ltd A pharmaceutical composition comprising an A-SMase inhibitor and an NO-donor
RU2376989C1 (ru) * 2008-10-09 2009-12-27 Фатима Якубовна Богатырева Способ лечения больных бесплодием, обусловленным ановуляцией на фоне хронического и острого воспаления органов малого таза
WO2010048264A2 (en) * 2008-10-23 2010-04-29 Combinatorx, Incorporated Methods and compositions for the treatment of immunoinflammatory disorders
US8420089B2 (en) 2008-11-25 2013-04-16 Alderbio Holdings Llc Antagonists of IL-6 to raise albumin and/or lower CRP
US8323649B2 (en) 2008-11-25 2012-12-04 Alderbio Holdings Llc Antibodies to IL-6 and use thereof
US9212223B2 (en) 2008-11-25 2015-12-15 Alderbio Holdings Llc Antagonists of IL-6 to prevent or treat thrombosis
US8337847B2 (en) 2008-11-25 2012-12-25 Alderbio Holdings Llc Methods of treating anemia using anti-IL-6 antibodies
US8992920B2 (en) * 2008-11-25 2015-03-31 Alderbio Holdings Llc Anti-IL-6 antibodies for the treatment of arthritis
US9452227B2 (en) 2008-11-25 2016-09-27 Alderbio Holdings Llc Methods of treating or diagnosing conditions associated with elevated IL-6 using anti-IL-6 antibodies or fragments
US20100160351A1 (en) * 2008-12-19 2010-06-24 Nuon Therapeutics, Inc. Pharmaceutical compositions and methods for treating hyperuricemia and related disorders
WO2010071865A1 (en) 2008-12-19 2010-06-24 Nuon Therapeutics, Inc. Pharmaceutical compositions and methods for treating hyperuricemia and related disorders
EP2298321A1 (en) * 2009-08-26 2011-03-23 Nordic Pharma Novel pharmaceutical compositions for treating IBD
WO2011032175A1 (en) 2009-09-14 2011-03-17 Nuon Therapeutics, Inc. Combination formulations of tranilast and allopurinol and methods related thereto
EP2504032A4 (en) 2009-11-24 2013-06-19 Alderbio Holdings Llc IL-6 ANTAGONISTS FOR PREVENTING OR TREATING THROMBOSIS
US9775921B2 (en) 2009-11-24 2017-10-03 Alderbio Holdings Llc Subcutaneously administrable composition containing anti-IL-6 antibody
TR201002473A2 (tr) 2010-03-31 2011-09-21 Mustafa Nevzat �La� Sanay�� A.�. Herpes zoster hastalığının bır opiat reseptör antagonist kullanılarak tedavi yöntemi.
TW201204719A (en) * 2010-06-02 2012-02-01 Ab Science Treatment of rheumatoid arthritis with masitinib
CA2818814A1 (en) 2010-11-23 2012-05-31 Alder Biopharmaceuticals, Inc. Anti-il-6 antibodies for the treatment of anemia
US20120252831A1 (en) * 2011-03-31 2012-10-04 Mustafa Nevzat Ilac Sanayii A.S. Compositions of opioid antagonists and methods for treating scleroderma therewith
CN106243096B (zh) * 2016-07-29 2019-11-29 上海璃道医药科技有限公司 三环类药物的新用途
US12121566B2 (en) 2019-01-30 2024-10-22 Horizon Therapeutics Usa, Inc. Methods for treating gout
MX2023000263A (es) 2020-07-16 2023-03-29 Dermavant Sciences GmbH Compuestos isoquinolina y su uso en el tratamiento del desequilibrio de ahr.

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2900249A (en) * 1956-06-01 1959-08-18 United States Steel Corp Surface blowing process for making steel
US4107306A (en) 1973-01-16 1978-08-15 The Regents Of The University Of Michigan Process for treating proliferative skin disease
US4034087A (en) 1973-12-17 1977-07-05 The Regents Of The University Of Michigan Pharmaceutical composition and process of treatment
EP0765475A1 (en) * 1994-05-18 1997-04-02 Ligand Pharmaceuticals, Inc. Screening for cytokine modulators
US6140337A (en) 1997-12-23 2000-10-31 Schering Corporation Methods for the treatment of mental disorders
US5900249A (en) 1998-02-09 1999-05-04 Smith; David J. Multicomponent pain relief topical medication
AU2662799A (en) * 1998-02-13 1999-08-30 Medinox, Inc. Modified pharmacologically active agents and improved therapeutic methods employing same
US6211171B1 (en) 1998-05-19 2001-04-03 Dalhousie University Use of antidepressants for local analgesia
US6677326B2 (en) 1999-03-15 2004-01-13 Arakis, Ltd. Corticosteroid formulation comprising less than 2.5 mg prednisolone for once daily administration
US6204245B1 (en) * 1999-09-17 2001-03-20 The Regents Of The University Of California Treatment of narcolepsy with immunosuppressants
DE60233414D1 (de) * 2001-07-09 2009-10-01 Combinatorx Inc Kombinationen für die behandlung entzündlicher erkrankungen

Also Published As

Publication number Publication date
CA2453399A1 (en) 2003-01-23
IS7099A (is) 2004-01-08
RU2004103537A (ru) 2005-02-27
NZ530764A (en) 2008-07-31
WO2003006026A1 (en) 2003-01-23
US20040116395A1 (en) 2004-06-17
US20040110734A1 (en) 2004-06-10
JP2004534841A (ja) 2004-11-18
ES2330837T3 (es) 2009-12-16
EP1414466A1 (en) 2004-05-06
RU2300379C2 (ru) 2007-06-10
MXPA04000222A (es) 2004-05-04
US6897206B2 (en) 2005-05-24
ZA200401004B (en) 2006-03-29
AU2002310511B8 (en) 2003-01-29
US20030078246A1 (en) 2003-04-24
KR20040026680A (ko) 2004-03-31
EP1414466B1 (en) 2009-08-19
AU2002310511B2 (en) 2007-12-06
CN1553804A (zh) 2004-12-08
EP1414466A4 (en) 2006-06-07
ATE439844T1 (de) 2009-09-15
DE60233414D1 (de) 2009-10-01
BR0211062A (pt) 2004-07-20
US20080280863A1 (en) 2008-11-13
US7335371B2 (en) 2008-02-26
SG152907A1 (en) 2009-06-29
PL368045A1 (en) 2005-03-21
IL159771A0 (en) 2004-06-20
US6955815B2 (en) 2005-10-18
US20100173881A1 (en) 2010-07-08
AR034746A1 (es) 2004-03-17
HRP20040102A2 (en) 2004-10-31

Similar Documents

Publication Publication Date Title
IS7099A (is) Efnasambönd til að meðhöndla bólgutruflanir
CY2013022I1 (el) Συνθεσεις για την θεραπευτικη αγωγη γαστρεντερικων διαταραχων
NO20043237L (no) Dihydrobenzodiazepin-2-onderivater for behandling av neurologiske forstyrrelser
NO20053678D0 (no) Kombinasjonsterapi for behandling av immuninflammatoriske forstyrrelser
NO20041386L (no) Kombinasjoner for bahandling av immunoinflammatoriske forstyrrelser
NO20031443D0 (no) Forbindelser nyttige for behandling av inflammatoriske sykdommer
NO20031442D0 (no) Morfolin-acetamidderivater for behandling av inflammatoriske sykdommer
IL162485A0 (en) Compounds for the treatment of inflammatory disorders
NO20042680L (no) Fremgangsmater for fremstilling av O-demetylvenflaxine
NO20020133D0 (no) Preparat for behandling av utvortes sekresjonsforstyrrelser
NO20026263L (no) Sulfonyl-pyrrolidin-derivater anvendelige for behandling av neurologiske forstyrrelser
IS7941A (is) Bensasepínafleiður til að meðhöndla taugasjúkdóma
AU2003228819A8 (en) Combinations for the treatment of inflammatory skin disorders
NO20040253L (no) Fremgangsmater for behandling av leverfibroser
NO20033803D0 (no) Karbamat for behandling av bevegelseslidelser
NO20033417D0 (no) Anvendelse av CD23-antagonister for behandling av neoplastiske forstyrrelser
DK1344526T3 (da) Midler til forebyggelse/behandling af inflammatoriske luftvejslidelser
NO20034123L (no) Fremgangsmåte for behandling av brennstoff
NO20032156L (no) Behandling av angstforstyrrelser
NO20030717L (no) Forbindelser for behandling av avhengighetsforstyrrelser
NO20012612D0 (no) Isonipecotamider for behandling av integren-formidlede lidelser
IS6098A (is) Ósantant til meðhöndlunar á skaptruflunum
DK1458703T3 (da) Isochromanforbindelser til behandling af CNS-lidelser
NO20025765D0 (no) Kombinasjonssett for behandling av malaria
NO20042542L (no) Anvendelse av ascomycin for behandling av blefarit

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application